Literature DB >> 32553518

Racial disparities in comorbid conditions among patients undergoing thyroidectomy for Graves' disease: An ACS-NSQIP analysis.

Anna C Beck1, Sonia L Sugg1, Ronald J Weigel1, Mary Belding-Schmitt1, James R Howe1, Geeta Lal2.   

Abstract

BACKGROUND: Studies indicate that racial disparities exist in the presentation and outcomes of patients undergoing thyroidectomy for cancer and benign disease. We examined the relationship between race, pre-operative characteristics and outcomes in patients undergoing thyroidectomy for GD.
METHODS: Patients were identified from the 2013-2016 American College of Surgeons NSQIP database using ICD-9/10 codes consistent with diffuse toxic goiter.
RESULTS: AA patients were more likely to have an ASA classification of ≥3 (41% vs 30%, p < 0.001), a higher rate of CHF (2.1% vs 0.5%, p = 0.01), hypertension (46% vs 32%, p < 0.001) and dyspnea (10% vs 5%, p < 0.001) compared to Non-Hispanic Caucasians (NH-C) patients. Complications were higher in patients with ASA≥3 and CHF but not affected by race.
CONCLUSIONS: Analysis of a national database of thyroidectomy for GD revealed a higher burden of preoperative comorbidities in AA patients compared to other races, although race was not an independent predictor of outcomes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Graves’ disease; NSQIP; Racial disparities; Thyroidectomy

Year:  2020        PMID: 32553518     DOI: 10.1016/j.amjsurg.2020.05.023

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

Review 1.  Disparities in Thyroid Care.

Authors:  Debbie W Chen; Michael W Yeh
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-04       Impact factor: 4.748

2.  Thyroidectomy for Graves' Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study.

Authors:  Sadaf Mohtashami; Keith Richardson; Veronique-Isabelle Forest; Alex Mlynarek; Richard J Payne; Michael Tamilia; Marc P Pusztaszeri; Michael P Hier; Nader Sadeghi; Marco A Mascarella
Journal:  Ann Otol Rhinol Laryngol       Date:  2021-06-01       Impact factor: 1.547

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.